First human test of new lung scarring drug shows early safety profile
NCT ID NCT05895565
Summary
This early-stage study tested a new drug called PMG1015 in 29 people with idiopathic pulmonary fibrosis (IPF), a serious lung scarring disease. The main goal was to check the drug's safety, side effects, and how it moves through the body at different doses. Researchers compared the drug to a placebo in a small group of patients not currently taking other IPF medications.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IPF are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
China-Japan Friendship Hospital
Beijing, Beijing Municipality, 100029, China
-
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, 210008, China
-
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, 200030, China
-
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, 200433, China
-
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, 510120, China
-
The Second Hospital of Anhui Medical University
Hefei, Anhui, 230000, China
-
Tongji Hospital Tongji Medical College of HUST
Wuhan, Hubei, 430030, China
Conditions
Explore the condition pages connected to this study.